Extended Low-Dose Apixaban After Provoked VTE: Marc Carrier Spotlights Major NEJM Results
Marc Carrier, Professor at Ottawa Hospital Research Institute, has posted on X:
”New in NEJM:
In patients with provoked VTE + enduring risk factors, extended low-dose apixaban (2.5 mg bid ×12 months): reduced recurrent VTE risk by nearly 90% (1.3% vs 10.0%): HR 0.13
Major bleeding was rare (1 pt).”
Find the full study here.
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, and Samuel Z. Goldhaber
Stay updated with Hemostasis Today.
-
Apr 23, 2026, 18:19Chokri Ben Lamine: Choosing the Right LMWH in Cancer Patients
-
Apr 23, 2026, 17:57Shalini R: Not All Blood Thinners Are the Same
-
Apr 23, 2026, 17:33Abdulaziz (Omar) Badran: Navigating the Clinical Complexity of Combined Red Cell Disorders
-
Apr 23, 2026, 17:19Kate Thomas: One Hour, One Donation, One Life Saved
-
Apr 23, 2026, 17:19Ameneh Eshghinejad: The First 72 Hours After SAH Are Critical for Balancing the Risks of Rebleeding and Thromboembolism
-
Apr 23, 2026, 17:18Katarina Ziakova: The WFH Shared Decision – Making Tool Is Driving Critical Conversations in Haemophilia Care
-
Apr 23, 2026, 17:14Paulus Kirchhof: Can We Improve Prevention of Cardiovascular Diseases?
-
Apr 23, 2026, 17:08Wolfgang Miesbach: 5‑Year Gene Therapy Data from WFH Congress 2026
-
Apr 23, 2026, 17:05Veronica Sanchez: The 2026 Guideline on the Management of Dyslipidemia